A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Janssen Research & Development, LLC
T3 Pharmaceuticals AG
Merck Sharp & Dohme LLC
Amgen
Tasly Pharmaceutical Group Co., Ltd
Beijing Biotech
Corcept Therapeutics
Nanjing Leads Biolabs Co.,Ltd
LARKSPUR BIOSCIENCES, INC.
University of Rochester
University of Southern California
University of Pennsylvania
University of Chicago
MBrace Therapeutics
Inmune Bio, Inc.
Merck Sharp & Dohme LLC
Centre Leon Berard
Eisai Inc.
Pathios Therapeutics Pty Ltd
Transgene
GlaxoSmithKline
Cytovation AS
Advanced Accelerator Applications
Daiichi Sankyo
Immunocore Ltd
LaNova Medicines Limited
Shanghai Hengrui Pharmaceutical Co., Ltd.
Cancer Vaccines Limited
Gustave Roussy, Cancer Campus, Grand Paris
Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Sanofi
MediLink Therapeutics (Suzhou) Co., Ltd.
Synthorx, Inc, a Sanofi company
Cytovation AS
Pardis Noor Medical Imaging and Cancer Center
Spago Nanomedical AB
Carrick Therapeutics Limited
Constellation Pharmaceuticals
Weill Medical College of Cornell University
GlaxoSmithKline
M.D. Anderson Cancer Center
Bristol-Myers Squibb
University of Maryland, Baltimore
Leucid Bio
Sanofi
First Hospital of China Medical University
Taiho Oncology, Inc.
Bayer
D'Or Institute for Research and Education
AHS Cancer Control Alberta